



EscharEx[®]




Superior to SOC - Sets a new bar for efficacy | Targets \$2B market opportunity | De-risked: based on a validated technology

Chronic Wound Debridement treatments are abundant but sub-optimal




EscharEx Provides Next-Generation Enzymatic Debridement for Wound Care - Wound Bed Preparation within a Week

VLU



DFU



EscharEx

- Investigational drug containing a sterile mixture of proteolytic enzymes
- Debrides chronic wounds in 4-6 daily applications
- Inline with current treatment workflows and reimbursement landscape
- Easy to use, daily topical application for outpatient setting
- Extended IP protection